Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients

Summary

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of GEP-NEN

Timeline

Start

2018-01-31

Primary completion

2020-12-30

Completion

2021-12-30

Drugs

Indications